Sign up for our Oncology Central weekly news round-up

Promising new strategies to target gene regulatory factors in T-cell acute lymphoblastic leukemia


There has been tremendous progress in the treatment of acute lymphoblastic leukemia (ALL) with modern chemotherapeutic regimens, especially in pediatric cases. However, patients with T-cell acute lymphoblastic leukemia (T-ALL) have a higher risk for early relapse than those with other ALL subtypes, and these cases have a substantially poorer overall prognosis [1]. Moreover, the intense treatment regimens used can result in significant morbidity. As newer target-based therapeutic agents continue to have promising effects in many types of cancer, these principles will surely be applied to new strategies for T-ALL treatment. Recent and ongoing research continues to uncover many of the molecular and genetic aberrations that occur during thymocyte development that lead to leukemic transformation and progression.

Click here to view the full article